Blood angiopoietin-2 predicts liver angiogenesis and fibrosis in hepatitis C patients
暂无分享,去创建一个
Y. Osawa | Taizo Mori | Sachiyo Yoshio | T. Kanto | T. Oide | Taiji Yamazoe | Yoshihiko Aoki | M. Korenaga | M. Imamura | Miku Okawara | Hironari Kawai | Y. Tsutsui | Y. Yoshida | Shiori Yoshikawa
[1] N. Sakamoto,et al. High serum angiopoietin‐2 level predicts non‐regression of liver stiffness measurement‐based liver fibrosis stage after direct‐acting antiviral therapy for hepatitis C , 2020, Hepatology research : the official journal of the Japan Society of Hepatology.
[2] C. Vanhove,et al. Angiopoietin‐2 Promotes Pathological Angiogenesis and Is a Therapeutic Target in Murine Nonalcoholic Fatty Liver Disease , 2019, Hepatology.
[3] R. Thadhani,et al. Serum Angiopoietin‐2 Predicts Mortality and Kidney Outcomes in Decompensated Cirrhosis , 2019, Hepatology.
[4] G. Giannelli,et al. Liver Angiopoietin‐2 Is a Key Predictor of D e N ovo or Recurrent Hepatocellular Cancer After Hepatitis C Virus Direct‐Acting Antivirals , 2018, Hepatology.
[5] Hui Zhao,et al. Mechanotransduction-modulated fibrotic microniches reveal the contribution of angiogenesis in liver fibrosis. , 2017, Nature materials.
[6] Shaker A. Mousa,et al. The Role of Angiogenesis in Cancer Treatment , 2017, Biomedicines.
[7] Xiao Liang,et al. Sorafenib: A potential therapeutic drug for hepatic fibrosis and its outcomes. , 2017, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
[8] Richard Moreau,et al. Liver sinusoidal endothelial cells: Physiology and role in liver diseases. , 2017, Journal of hepatology.
[9] M. Borque,et al. Angiopoietin-2/angiopoietin-1 as non-invasive biomarker of cirrhosis in chronic hepatitis C , 2016, World journal of gastroenterology.
[10] D. Siemann,et al. Targeting the Angiopoietin-2/Tie-2 axis in conjunction with VEGF signal interference. , 2016, Cancer letters.
[11] K. Alitalo,et al. Opposing actions of angiopoietin-2 on Tie2 signaling and FOXO1 activation. , 2016, The Journal of clinical investigation.
[12] V. Shah,et al. Sinusoidal communication in liver fibrosis and regeneration. , 2016, Journal of hepatology.
[13] K. Alitalo,et al. Tie1 controls angiopoietin function in vascular remodeling and inflammation. , 2016, The Journal of clinical investigation.
[14] L. DeLeve. Liver sinusoidal endothelial cells in hepatic fibrosis , 2015, Hepatology.
[15] G. Elpek. Angiogenesis and liver fibrosis. , 2015, World journal of hepatology.
[16] F. Rodríguez-Pascual,et al. The profibrotic role of endothelin-1: is the door still open for the treatment of fibrotic diseases? , 2014, Life sciences.
[17] H. Augustin,et al. Angiopoietin-2: an attractive target for improved antiangiogenic tumor therapy. , 2013, Cancer research.
[18] H. Nagai,et al. Serum VEGF as a tumor marker in patients with HCV-related liver cirrhosis and hepatocellular carcinoma. , 2013, Anticancer research.
[19] Jun-ji Ma,et al. New insights into the antifibrotic effects of sorafenib on hepatic stellate cells and liver fibrosis. , 2010, Journal of hepatology.
[20] K. Iwaisako,et al. Hepatic stellate cells secrete angiopoietin 1 that induces angiogenesis in liver fibrosis. , 2008, Gastroenterology.
[21] M. Borque,et al. The potential of angiogenesis soluble markers in chronic hepatitis C , 2005, Hepatology.
[22] D. Auclair,et al. BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis , 2004, Cancer Research.
[23] H. Yu,et al. Overexpression of VEGF and Angiopoietin 2: A Key to High Vascularity of Hepatocellular Carcinoma? , 2003, Modern Pathology.
[24] Hilde van der Togt,et al. Publisher's Note , 2003, J. Netw. Comput. Appl..
[25] D. Rockey,et al. Cellular localization of endothelin‐1 and increased production in liver injury in the rat: Potential for autocrine and paracrine effects on stellate cells , 1998, Hepatology.